Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-7691Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pradhan, Swetalina | - |
| dc.contributor.author | Schwartz, Robert | - |
| dc.contributor.author | Patil, Anant | - |
| dc.contributor.author | Grabbe, Stephan | - |
| dc.contributor.author | Goldust, Mohamad | - |
| dc.date.accessioned | 2022-09-07T08:30:33Z | - |
| dc.date.available | 2022-09-07T08:30:33Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/7706 | - |
| dc.description.abstract | Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and visceral. The visceral form is most dangerous and can result in death. Although leishmaniasis is an ancient disease, its treatment is still challenging. Several drugs, differing in their cost, toxicity, treatment duration and emergence of drug resistance, are used for different types of leishmaniasis. To overcome these limitations, the search for newer drugs and other treatments continues. In this article, we discuss conventional drugs, other treatments, including newer options such as immunotherapy and immunochemotherapy, and future prospects for leishmaniasis treatment. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | Treatment options for leishmaniasis | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-7691 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | Clinical and experimental dermatology | de |
| jgu.journal.volume | 47 | de |
| jgu.journal.issue | 3 | de |
| jgu.pages.start | 516 | de |
| jgu.pages.end | 521 | de |
| jgu.publisher.year | 2022 | - |
| jgu.publisher.name | Wiley-Blackwell | de |
| jgu.publisher.place | Oxford u.a | de |
| jgu.publisher.issn | 1365-2230 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1111/ced.14919 | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | JGU-Publikationen | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | treatment_options_for_leishma-20220907103110563.pdf | 77.84 kB | Adobe PDF | View/Open |